To provide the Highest Level of Excellence as a Licensed Worldwide Pharmaceutical Wholesaler.

What Is A Pharmaceutical Distributor?


About Pharmaceutical Distributors

What Is A Pharmaceutical Distributor

A pharmaceutical distributor is a business that is involved in the distribution of medicines. There are a few considerations that must be taken into account when distributing drugs, especially when it comes to the safety and security of the drugs. One of the main considerations involves the cold chain management of certain medications.

Generic products offer wholesalers a wider avenue for price negotiation

The wholesaler industry plays a critical role in the health care sector. Besides providing drugs to the public, they also play a significant role in the supply chain. For instance, did you know that the COVID-19 vaccine was largely delivered by the likes of McKesson, AmerisourceBergen and Cardinal Health? One could argue that these giants have a vested interest in ensuring that the products they supply are priced competitively. While they may not be in the business of supplying cheap generics to their customers, they do have the clout to negotiate price increases with manufacturers. In the end, this translates into higher quality healthcare for the patient and lower prices for the consumer.

A review of the state of the art in drug distribution in Medicaid revealed that six out of the ninety generic products surveyed sported price increases of greater than 100 percent in 2017. Assuming that the generics were in the hands of the pros, the costs to consumers would likely be a fraction of the sums that were previously paid out of pocket. Some of the largest wholesalers also have the clout to convince small independent pharmacies to enter into a preferred contract. This means more business for the wholesalers and more business for the smaller operators.

Despite a number of regulatory challenges, the pharmaceutical industry is still a lucrative one to be reckoned with. To some extent, this is a result of the industry’s vertical integration. Likewise, the industry is well versed in the latest medical advances. Whether it’s the burgeoning telemedicine industry or the rise of managed care, the industry is adapting to changing needs.

Pharmacists should share priorities

As a pharmacist, you should be aware of the importance of sharing your priorities with pharmaceutical distributors. This will help them to better understand your practice and provide services that benefit your community pharmacy.

Pharmacists are well-positioned to share their priorities with distributors, because they have a global understanding of big-picture issues. They can work together to create a healthy bottom line and ensure optimal patient outcomes.

A study of pharmacists in three different groups found that their task prioritization differs. This may affect the amount of time they devote to certain activities in their daily practices.

One group, for example, is less likely to prioritize Quality assurance, or QA, than another. Similarly, another group is less likely to give the importance of a patient interview as much priority as another. The differences are due to differences in the ranking of activities considering personnel and financial management.

A third group consists of pharmacists who focus on quality management. They might have higher-than-average preferences for these activities.

On the other hand, the other two groups are more likely to rank Logistics and Pharmacy Management lower. Despite this, all of the participating pharmacists give a high level of priority to Cognitive Pharmaceutical Services, or CPS.

It is important for pharmacists to recognize and emphasize the importance of adherence in chronic disease control. They should also encourage patients to take advantage of drug delivery services.

Pharmacists should educate patients about common adverse reactions. In addition, they should make it a point to remind them of the importance of taking medications on time and maintaining a regular schedule. During a COVID-19 pandemic, this can be particularly challenging.

To address this, policymakers should join forces to enable community pharmacists to increase their commitment to CPS. However, this can be a difficult task for pharmacists, since they have to balance their time between traditional activities and cognitive pharmaceutical services.

Pharmacists should consider how their time and resources are spent in order to identify the activities they prefer. They should delegate other activities to support staff so that they can focus on more important tasks.

Gross and net margins

When evaluating a pharmaceutical distributor’s net and gross profit margins, it is important to consider a variety of factors. The most important is the number of products sold. If a company sells multiple goods, it’s important to understand the different costs associated with each one. It’s also vital to take into consideration the operating expenses. A large up-front cost can be a detriment to a company’s gross profit margin.

In the USA, pharmaceutical companies have higher price-cost margins than most other countries. However, the United States is well known for its opaque reimbursement system. Price controls often affect pharmaceutical price-cost margins. This is because companies rely on revenue from after-the-fact rebates and fees.

Researchers estimate that the US expenditure on pharmaceutical drugs was $480 billion in 2016. Of this total, wholesalers captured approximately $18 billion. While PBMs and retail and specialty pharmacies captured about 20 percent of this total.

The remaining portion was retained as gross profits within the supply chain. To quantify this, researchers quantified the gross profits retained by each supply chain participant.

After combining these data sets, regressions were performed with 6889 observations. These results showed that the overall gross and net profit margins of pharmaceutical distributors were on average 30 to 50 percent.

In addition, it was found that pharmaceutical companies were less profitable than companies in the S&P 500. Companies in the S&P 500 had a median EBITDA margin of 29.4%, while pharmaceutical companies had a median EBITDA margin of 19%. Although the differential profit margin was 6.8%, it was within the 95% confidence interval.

A multivariable median regression model was used to compare the net and gross profit margins of pharmaceutical companies and S&P 500 companies. Controls included company size, market capitalization, and year fixed effects. Using these control variables, researchers estimated the median and differentiating profit margins for each sector. Specifically, the pharmaceutical and S&P 500 data sets were compared with the following subsectors of the health care industry: pharmacists, medical practitioners, and physicians.

Compared to other health care industries, pharmaceutical companies had the highest median and differential gross and net profit margins. However, the difference was small, as only about half of the total was captured by these companies.

DSCSA requires pharmacies to transact only with authorized trading partners

The Drug Supply Chain Security Act (DSCSA) was passed in 2013. It was designed to enhance accountability for prescription drugs. To help achieve this goal, DSCSA requires all parts of the pharmaceutical supply chain to comply with the law.

The DSCSA includes several requirements for pharmacies, wholesale distributors, manufacturers and third-party logistics providers. These requirements will be phased in over the next ten years.

During the first phase of DSCSA implementation, all suppliers and trading partners in the supply chain are required to work only with authorized trading partners. Authorized trading partners include drug manufacturers, distributors, repackagers, wholesalers and dispensers. Each type of supplier must meet DSCSA requirements and be in compliance with certain reporting requirements.

A pharmacy will be responsible for tracking and tracing products and medication movements through the supply chain. In addition to receiving transaction information, pharmacies are tasked with investigating suspected counterfeit or illegitimate products. They must report suspicious products to the FDA and notify all trading partners of any illegitimate products.

DSCSA provides pharmacists with tools to identify and investigate illegitimate products. Pharmacies must also ensure that they receive Transaction History, including the Transaction Statement and the address of the transferee.

As part of the DSCSA implementation process, re-packagers and wholesalers must provide the DSCSA-required Transaction History, including Transaction Information and Transaction Statement. Repackagers and wholesalers are prohibited from accepting any product from a manufacturer or other dispensing entity that does not provide the full T3 information. This information will not be provided in paper form.

While this process can be difficult to implement, it is important to remain vigilant and maintain compliance with the DSCSA. By doing so, you can protect your patients, consumers, and your entire health system.

Whether you are a hospital or retail pharmacy, your role in the pharmaceutical supply chain is essential. You will need to review packaging, develop a list of all drug suppliers and maintain a detailed inventory of all drug products received from each supplier.

If you have any questions or concerns about your pharmacy’s DSCSA compliance, contact a Hinshaw & Culbertson LLP attorney for assistance. With extensive experience in advising clients with all aspects of pharmacy and medical supply chain operations, we can help you to achieve your compliance goals.